Rhythm Pharmaceuticals Inc., a global commercial-stage biopharmaceutical company, has announced significant progress in its regulatory review process. The company remains on track to submit a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) and a Type II variation request to the European Medicines Agency for its drug, setmelanotide, targeted at treating patients with acquired hypothalamic obesity. This follows the successful achievement of the primary endpoint in a pivotal Phase 3 trial, which demonstrated a -19.8% placebo-adjusted BMI reduction in 120 patients. Additionally, Rhythm Pharmaceuticals is anticipated to complete enrollment in a Phase 3 trial substudy investigating the use of setmelanotide in congenital hypothalamic obesity by the second half of 2025.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。